Table 2 Comparison of the alteration frequency of STRs in different malignant cancers (%).

From: Evaluation of genetic instability of short tandem repeats in hepatocellular carcinoma

Locus

HCC (this study)

(n = 101)

HCC (previous study)3

(n = 30)

CRC2 (n = 129)

GC2 (n = 121)

RCC3

(n = 22)

PC3 (n = 35)

BC3 (n = 36)

LC4

(n = 75)

PTC7 (n = 68)

D2S1338

6.93%

6.67%

13.18%

15.70%

4.55%

2.86%

2.78%

5.33%

5.88%

TPOX

4.95%

3.33%

7.75%

5.79%

0.00%

0.00%

2.78%

4.00%

2.94%

D3S1358

7.92%

10.00%

9.30%

12.40%

13.64%

5.71%

5.56%

6.67%

2.94%

FGA

47.52%

30.00%

24.03%

19.33%

4.55%

6.45%

2.78%

5.33%

2.94%

D5S818

14.85%

0.00%

24.81%

12.40%

0.00%

8.57%

0.00%

9.33%

1.47%

CSF1PO

10.89%

3.33%

23.26%

21.49%

0.00%

6.25%

2.78%

2.67%

4.41%

D6S1043

21.78%

26.67%

13.18%

17.50%

15.00%

7.14%

2.78%

1.33%

1.47%

D7S820

7.92%

0.00%

10.08%

14.05%

4.55%

2.94%

2.78%

2.67%

1.47%

D8S1179

22.77%

16.67%

16.28%

15.70%

9.09%

5.71%

11.11%

1.33%

2.94%

TH01

9.90%

3.33%

10.08%

9.09%

9.09%

2.86%

8.33%

5.33%

1.47%

D12S391

20.79%

13.33%

13.95%

16.53%

4.55%

9.68%

8.33%

6.67%

2.94%

vWA

14.85%

13.33%

16.67%

16.81%

4.55%

11.43%

8.33%

2.67%

0.00%

D13S317

23.76%

36.67%

13.28%

9.92%

4.55%

2.94%

11.11%

4.00%

2.94%

Penta E

13.86%

6.67%

26.56%

19.33%

9.09%

7.14%

11.11%

0.00%

2.94%

D16S539

42.57%

23.33%

9.30%

14.88%

0.00%

2.86%

11.11%

2.67%

0.00%

D18S51

17.82%

6.67%

43.41%

21.85%

9.09%

9.38%

5.56%

4.00%

1.47%

D19S433

5.94%

0.00%

14.73%

14.05%

0.00%

2.86%

0.00%

1.33%

1.47%

Penta D

16.83%

3.33%

15.50%

16.81%

13.64%

6.45%

0.00%

5.33%

0.00%

D21S11

15.84%

3.33%

14.73%

10.74%

9.09%

6.45%

0.00%

1.33%

2.94%

Average

17.25%

10.88%

16.85%

14.97%

6.05%

5.67%

5.12%

3.79%

2.24%

Back to article page